Idenix has been talking partner for eons as well, so you guys need to be a little more consistent :)
It takes time, of course, but the important point is that IDIX has not had to resort to hiring a banker, which I assume is because the interest for their HCV compounds is in fact there. If we see a PR from IDIX (and ACHN for that matter) of the need to involve a banker to license one of their HCV compounds, I will gladly eat crow. ; )
Market Data 
Markets 
AI
